Literature DB >> 18854614

Current status of anticoagulation therapy for elderly atrial fibrillation patients in Japan: from Hokuriku atrial fibrillation trial.

Hiroshi Furusho1, Masayuki Takamura, Shigeo Takata, Satoru Sakagami, Motoaki Hirazawa, Takeshi Kato, Hisayoshi Murai, Masaki Okajima, Shuichi Kaneko.   

Abstract

BACKGROUND: The number of the elderly patients with atrial fibrillation (AF) is increasing, but the current status of anticoagulation therapy for elderly patients with AF in Japan is not clear. METHODS AND
RESULTS: Among the patients registered in the "Hokuriku Atrial Fibrillation Trial (HAT) 1", 365 AF patients aged > or =65 years were enrolled in this study. Warfarin was used for significantly less patients in the oldest group aged > or =85 years (36%) than in younger populations, but the percentage of antiplatelet use in this oldest population was largest (40%). The elderly group (> or =85 years) was compared with a younger group aged between 75 and 84 years. Warfarin was given to 61% of the younger group compared with 36% in the elderly group. In the younger group, the more thromboembolic risks they had according to CHADS2 score, the more warfarin was used, whereas there was no clear trend in the usage of warfarin in the elderly group.
CONCLUSIONS: The number of elderly Japanese patients with AF taking warfarin is currently low, but because the population of elderly AF patients will increase in the future, there is a need for safe and suitable anticoagulation therapy for elderly patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854614     DOI: 10.1253/circj.cj-08-0290

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  3 in total

1.  Correlation between CHADS2 score and anticoagulant use in atrial fibrillation: Results of a mini-survey.

Authors:  Gerry Cartman; Mark Blostein; Mark J Eisenberg
Journal:  Exp Clin Cardiol       Date:  2013

2.  Could some geriatric characteristics hinder the prescription of anticoagulants in atrial fibrillation in the elderly?

Authors:  Paule Denoël; Jacques Vanderstraeten; Pierre Mols; Thierry Pepersack
Journal:  J Aging Res       Date:  2014-09-10

3.  Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa).

Authors:  Yutaka Hatori; Hiroyuki Sakai; Tomoyuki Kunishima; Nobuo Hatori; Lin Chen; Tomoaki Ishigami; Naoki Satoh
Journal:  J Arrhythm       Date:  2016-08-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.